Hollsteen
← Palantir

Research and development

Flow – sum over the period · $M

QuartersFiscal years

$MResearch and development · Q1 2016: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Research and development · Q2 2016: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Research and development · Q3 2016: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Research and development · Q4 2016: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Research and development · Q1 2017: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Research and development · Q2 2017: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Research and development · Q3 2017: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Research and development · Q4 2017: not reported – Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.Research and development · Q1 2018: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Research and development · Q2 2018: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Research and development · Q3 2018: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Research and development · Q4 2018: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Research and development · Q1 2019: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Research and development · Q2 2019: not reported – Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.Research and development · Q3 2019: $76.0M · 10-Q 0001193125-20-292177 filed Nov 13, 2020Research and development · Q4 2019: $76.0M · derived · 10-K 0001193125-21-060650 filed Feb 26, 2021Research and development · Q1 2020: $66.0M · 10-Q 0001193125-21-159222 filed May 12, 2021Research and development · Q2 2020: $87.0M · 10-Q 0000950123-21-010430 filed Aug 12, 2021Research and development · Q3 2020: $314M · 10-Q 0001193125-20-292177 filed Nov 13, 2020Research and development · Q4 2020: $94.0M · derived · 10-K 0001193125-22-050913 filed Feb 24, 2022Research and development · Q1 2021: $98.0M · 10-Q 0001193125-21-159222 filed May 12, 2021Research and development · Q2 2021: $111M · 10-Q 0000950123-21-010430 filed Aug 12, 2021Research and development · Q3 2021: $94.0M · 10-Q 0001193125-21-323920 filed Nov 9, 2021Research and development · Q4 2021: $84.0M · derived · 10-K 0001321655-23-000011 filed Feb 21, 2023Research and development · Q1 2022: $89.0M · 10-Q 0001321655-22-000006 filed May 9, 2022Research and development · Q2 2022: $88.0M · 10-Q 0001321655-22-000016 filed Aug 8, 2022Research and development · Q3 2022: $101M · 10-Q 0001321655-22-000032 filed Nov 7, 2022Research and development · Q4 2022: $82.0M · derived · 10-K 0001321655-24-000022 filed Feb 20, 2024Research and development · Q1 2023: $90.0M · 10-Q 0001321655-23-000044 filed May 9, 2023Research and development · Q2 2023: $100M · 10-Q 0001321655-23-000090 filed Aug 8, 2023Research and development · Q3 2023: $106M · 10-Q 0001321655-23-000118 filed Nov 3, 2023Research and development · Q4 2023: $109M · derived · 10-K 0001321655-25-000022 filed Feb 18, 2025Research and development · Q1 2024: $110M · 10-Q 0001321655-24-000071 filed May 7, 2024Research and development · Q2 2024: $109M · 10-Q 0001321655-24-000135 filed Aug 6, 2024Research and development · Q3 2024: $118M · 10-Q 0001321655-24-000209 filed Nov 5, 2024Research and development · Q4 2024: $172M · derived · 10-K 0001321655-26-000011 filed Feb 17, 2026Research and development · Q1 2025: $135M · 10-Q 0001321655-25-000066 filed May 6, 2025Research and development · Q2 2025: $135M · 10-Q 0001321655-25-000106 filed Aug 5, 2025Research and development · Q3 2025: $144M · 10-Q 0001321655-25-000131 filed Nov 4, 2025Research and development · Q4 2025: $144M · derived · 10-K 0001321655-26-000011 filed Feb 17, 2026Research and development · Q1 2026: $161M · 10-Q 0001321655-26-000028 filed May 5, 2026Research and development · Q2 2026: $193M · 10-Q 0001321655-26-000041 filed Aug 4, 2026not reported14419376314Q1 2016Q2 2026
$MResearch and development · Q3 2024: $118M · 10-Q 0001321655-24-000209 filed Nov 5, 2024Research and development · Q4 2024: $172M · derived · 10-K 0001321655-26-000011 filed Feb 17, 2026Research and development · Q1 2025: $135M · 10-Q 0001321655-25-000066 filed May 6, 2025Research and development · Q2 2025: $135M · 10-Q 0001321655-25-000106 filed Aug 5, 2025Research and development · Q3 2025: $144M · 10-Q 0001321655-25-000131 filed Nov 4, 2025Research and development · Q4 2025: $144M · derived · 10-K 0001321655-26-000011 filed Feb 17, 2026Research and development · Q1 2026: $161M · 10-Q 0001321655-26-000028 filed May 5, 2026Research and development · Q2 2026: $193M · 10-Q 0001321655-26-000041 filed Aug 4, 2026144193118Q3 2024Q2 2026Q3 2025
Q3 2025
144$M
All values (28)
PeriodValue ($M)Status
Q2 2026193reported
Q1 2026161reported
Q4 2025144derived
Q3 2025144reported
Q2 2025135reported
Q1 2025135reported
Q4 2024172derived
Q3 2024118reported
Q2 2024109reported
Q1 2024110reported
Q4 2023109derived
Q3 2023106reported
Q2 2023100reported
Q1 202390reported
Q4 202282derived
Q3 2022101reported
Q2 202288reported
Q1 202289reported
Q4 202184derived
Q3 202194reported
Q2 2021111reported
Q1 202198reported
Q4 202094derived
Q3 2020314reported
Q2 202087reported
Q1 202066reported
Q4 201976derived
Q3 201976reported
Q1 2018 – Q2 2019–not reported (6 periods): Before the first 10-Q (Q3 FY2019) there are no quarterly statements in the SEC XBRL data; fiscal years 2018/2019 appear as comparatives in the later 10-K.
Q1 2016 – Q4 2017–not reported (8 periods): Palantir has been an SEC filer only since its 2020 listing; tagged financial statements begin with FY2018. FY2016 and FY2017 not reported.

Show reported periods only · CSV with all sources · Technical ID: rnd

More metrics for Palantir

Value drivers

Income statement

Per share

Balance sheet

Cash flow

Debt and interest

Sources & calculation
Value
$144M
Period
Q3 2025, ended Sep 30, 2025 · quarterly value (3 months, not cumulative)
Source
10-Q, filed Nov 4, 2025 · 0001321655-25-000131
Location
us-gaap:ResearchAndDevelopmentExpense
Confidence
1. – directly from an XBRL fact in the filing (or calculated exactly from it)

Versions

v1$144MNov 4, 202510-Q 0001321655-25-000131reported · confidence 1. · current